Emerging therapies for multiple myeloma

Klaus Podar*, Yu Tzu Tai, Teru Hideshima, Sonia Vallet, Paul G. Richardson, Kenneth C. Anderson

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Review article

50 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a clonal plasma cell malignancy clinically characterized by osteolytic lesions, immunodeficiency, and renal disease. There are an estimated 750,000 people diagnosed with MM worldwide, with a median overall survival of 3 - 5 years. Besides chromosomal aberrations, translocations, and mutations in essential growth and tumor-suppressor genes, accumulating data strongly highlight the pathophysiologic role of the bone marrow (BM) microenvironment in MM pathogenesis. Based on this knowledge, several novel agents have been identified, and treatment options in MM have fundamentally changed during the last decade. Thalidomide, bortezomib, and lenalidomide have been incorporated into conventional cytotoxic and transplantation regimens, first in relapsed and refractory and now also in newly diagnosed MM. Despite these significant advances, there remains an urgent need for more efficacious and tolerable drugs. Indeed, a plethora of preclinical agents awaits translation from the bench to the bedside. This article reviews the scientific rationale of new therapy regimens and newly identified therapeutic agents - small molecules as well as therapeutic antibodies - that hold promise to further improve outcome in MM.

Original languageEnglish
Pages (from-to)99-127
Number of pages29
JournalExpert Opinion on Emerging Drugs
Volume14
Issue number1
DOIs
Publication statusPublished - Mar 2009
Externally publishedYes

Keywords

  • Bone marrow microenvironment
  • Combination therapy
  • Multiple myeloma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Emerging therapies for multiple myeloma'. Together they form a unique fingerprint.

Cite this